See more : JLEN Environmental Assets Group Limited (JLEN.L) Income Statement Analysis – Financial Results
Complete financial analysis of Rhythm Pharmaceuticals, Inc. (RYTM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Rhythm Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- ZOOZ Power Ltd. Warrant (ZOOZW) Income Statement Analysis – Financial Results
- Zhonghua Gas Holdings Limited (8246.HK) Income Statement Analysis – Financial Results
- Ningxia Qinglong Pipes Industry Group Co., Ltd. (002457.SZ) Income Statement Analysis – Financial Results
- Japan Business Systems, Inc. (5036.T) Income Statement Analysis – Financial Results
- Silkwave Inc (0471.HK) Income Statement Analysis – Financial Results
Rhythm Pharmaceuticals, Inc. (RYTM)
About Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 77.43M | 23.64M | 3.15M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 9.30M | 2.13M | 599.00K | 690.00K | 834.00K | 442.00K | 223.00K | 144.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 68.13M | 21.51M | 2.56M | -690.00K | -834.00K | -442.00K | -223.00K | -144.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 87.99% | 90.98% | 81.01% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 134.95M | 108.63M | 104.13M | 90.45M | 109.45M | 50.34M | 22.89M | 19.59M | 7.15M | 5.28M | 18.02M | 15.68M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 28.08M | 9.52M | 6.31M | 3.43M | 1.21M | 3.43M | 2.46M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 117.53M | 92.03M | 68.49M | 46.13M | 36.55M | 28.08M | 9.52M | 6.31M | 3.43M | 1.21M | 3.43M | 2.46M |
| Other Expenses | 0.00 | -790.00K | 100.00M | 0.00 | 0.00 | 0.00 | -1.86M | 0.00 | -500.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 252.48M | 200.66M | 172.61M | 136.58M | 146.00M | 78.42M | 32.41M | 25.91M | 10.57M | 6.49M | 21.45M | 18.14M |
| Cost & Expenses | 261.79M | 202.80M | 173.21M | 136.58M | 146.00M | 78.42M | 32.41M | 25.91M | 10.57M | 6.49M | 21.45M | 18.14M |
| Interest Income | 13.95M | 4.03M | 447.00K | 2.58M | 5.27M | 4.35M | 566.00K | 33.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 13.89M | 5.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.76M | 1.40M | 1.16M | 690.00K | 834.00K | 442.00K | 223.00K | 144.00K | 500.00K | 6.49M | 20.00K | 17.00K |
| EBITDA | -168.46M | -174.52M | -68.45M | -135.89M | -145.17M | -77.98M | -32.19M | -25.76M | -10.07M | 0.00 | -21.41M | -18.12M |
| EBITDA Ratio | -217.58% | -744.22% | -5,391.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -184.36M | -179.16M | -170.06M | -136.58M | -146.00M | -78.42M | -32.41M | -25.91M | -10.57M | -6.49M | -21.45M | -18.14M |
| Operating Income Ratio | -238.10% | -757.92% | -5,391.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 243.00K | -1.96M | 100.45M | 2.58M | 5.27M | 4.35M | -1.30M | 33.00K | -500.00K | 0.00 | 17.00K | 8.00K |
| Income Before Tax | -184.11M | -181.12M | -69.61M | -134.00M | -140.73M | -74.06M | -33.71M | -25.87M | -11.07M | -6.49M | -21.43M | -18.13M |
| Income Before Tax Ratio | -237.79% | -766.22% | -2,207.10% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 564.00K | 1.96M | -1.61M | -3.27M | -6.11M | 4.35M | 1.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -184.68M | -183.08M | -68.01M | -130.73M | -134.62M | -74.06M | -33.71M | -25.87M | -11.07M | -6.49M | -21.43M | -18.13M |
| Net Income Ratio | -238.52% | -774.52% | -2,156.21% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.20 | -3.51 | -1.37 | -2.96 | -3.70 | -2.39 | -2.54 | -1.55 | -0.66 | -0.64 | -0.43 | -0.36 |
| EPS Diluted | -3.20 | -3.51 | -1.37 | -2.96 | -3.70 | -2.39 | -2.54 | -1.55 | -0.66 | -0.64 | -0.43 | -0.36 |
| Weighted Avg Shares Out | 57.67M | 52.12M | 49.60M | 44.13M | 36.42M | 31.00M | 13.27M | 16.73M | 16.73M | 10.20M | 50.27M | 50.27M |
| Weighted Avg Shares Out (Dil) | 57.67M | 52.12M | 49.60M | 44.13M | 36.42M | 31.00M | 13.27M | 16.73M | 16.73M | 10.20M | 50.27M | 50.27M |
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2023 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Misses Revenue Estimates
Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
Rhythm Pharmaceuticals, Inc. (RYTM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
Source: https://incomestatements.info
Category: Stock Reports